Suppr超能文献

游离脂肪酸受体作为肝脏疾病的介质和治疗靶点

Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease.

作者信息

Secor Jordan D, Fligor Scott C, Tsikis Savas T, Yu Lumeng J, Puder Mark

机构信息

Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

出版信息

Front Physiol. 2021 Apr 7;12:656441. doi: 10.3389/fphys.2021.656441. eCollection 2021.

Abstract

Free fatty acid receptors (FFARs) are a class of G protein-coupled receptors (GPCRs) that have wide-ranging effects on human physiology. The four well-characterized FFARs are FFAR1/GPR40, FFAR2/GPR43, FFAR3/GPR41, and FFAR4/GPR120. Short-chain (<6 carbon) fatty acids target FFAR2/GPR43 and FFAR3/GPR41. Medium- and long-chain fatty acids (6-12 and 13-21 carbon, respectively) target both FFAR1/GPR40 and FFAR4/GPR120. Signaling through FFARs has been implicated in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), intestinal failure-associated liver disease (IFALD), and a variety of other liver disorders. FFARs are now regarded as targets for therapeutic intervention for liver disease, diabetes, obesity, hyperlipidemia, and metabolic syndrome. In this review, we provide an in-depth, focused summary of the role FFARs play in liver health and disease.

摘要

游离脂肪酸受体(FFARs)是一类对人体生理有广泛影响的G蛋白偶联受体(GPCRs)。四种已被充分表征的FFARs分别是FFAR1/GPR40、FFAR2/GPR43、FFAR3/GPR41和FFAR4/GPR120。短链(<6个碳原子)脂肪酸作用于FFAR2/GPR43和FFAR3/GPR41。中链和长链脂肪酸(分别为6 - 12个和13 - 21个碳原子)则作用于FFAR1/GPR40和FFAR4/GPR120。通过FFARs的信号传导与非酒精性脂肪性肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、肠衰竭相关肝病(IFALD)以及多种其他肝脏疾病有关。FFARs现在被视为肝病、糖尿病、肥胖、高脂血症和代谢综合征治疗干预的靶点。在本综述中,我们对FFARs在肝脏健康和疾病中所起的作用进行了深入、重点突出的总结。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b08d/8058363/878f11615416/fphys-12-656441-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验